If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying.
Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's what they are recommending to clients:
James Hardie Industries plc (ASX: JHX)
Bell Potter sees housing and renovation trends in North America as a tailwind for James Hardie, the fibre cement building materials specialist. It has a buy rating and $63.00 price target on its shares. The broker continues to like the company's exposure to structural housing demand. It said: "In our view, JHX is poised for continued earnings expansion, driven by the structural shift towards fibre cement in the US. Households in the US continue to shift to fibre cement cladding from vinyl/timber, providing a multi-year runway for JHX's revenue and profit growth."
ResMed Inc. (ASX: RMD)
Medical device company ResMed could be an ASX 200 stock to buy. The team at Macquarie is bullish and sees plenty of value in its shares at current levels. And with its market leadership in CPAP devices and strong recurring revenue model, Macquarie remains confident in its long-term growth story. The broker has an outperform rating and $45.10 price target.
Telix Pharmaceuticals Ltd (ASX: TLX)
A third ASX 200 stock that could be a top buy is Telix. It has impressed in recent times with its strong earnings growth and a pipeline packed with potential lucrative therapies. Bell Potter is a big fan and highlights its established revenue stream from Illuccix and sees future product approvals (like Gozellix and Zircaix) as key drivers of potential upside. It also notes that its current valuation leaves room for meaningful gains if the company delivers on its plans. Bell Potter has a buy rating and $36.00 price target on its shares.
WiseTech Global Ltd (ASX: WTC)
Macquarie is also bullish on logistics software giant WiseTech, noting its strong market position and structural growth prospects. The broker highlights that the company is optimising for long-term value creation and feels investors should be patient following recent product launch delays. The broker has an outperform rating and $152.70 price target on its shares.
Xero Ltd (ASX: XRO)
Finally, Goldman Sachs thinks that Xero could be a top ASX 200 stock for investors to buy. The broker sees it as a long-term compounder in the cloud accounting space, previously highlighting a multi-decade runway for growth. This is thanks to its total addressable market sitting at about 100 million small to medium sized businesses, compared to its current subscriber base of approximately 4 million. Goldman has a buy rating and $201.00 price target on Xero's shares.
The post 5 top ASX 200 stocks that brokers rate as buys after the market selloff appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in ResMed, WiseTech Global, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, ResMed, Telix Pharmaceuticals, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, WiseTech Global, and Xero. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025